Roche announces positive clinical results for petrelintidel phase, with significant weight loss observed once a week
On March 5, 2026, Roche announced that it is developing a weight loss drug called petrelintide in comparison to a placebo! The ZUPREME-1 test achieved positive top line results. The study was designed for gender balance and included a total of 493 overweight and obese subjects (with an average BMI of 37 kg/m2).
The main endpoint of the study was achieved: petrelintide was administered subcutaneously once a week (with increasing doses every 4 weeks), and at 28 weeks, all 5 treatment groups achieved statistically significant and clinically significant weight loss compared to baseline, significantly better than the placebo group.
The weight loss effect lasted until week 42: According to the efficacy analysis set, the average weight of the subjects decreased by 10.7% compared to baseline, while the placebo group decreased by 1.7%.
In the queue with the most significant weight loss, 98% of subjects receiving petrelintide treatment completed and maintained the target dose, highlighting their good tolerability. The weight loss results obtained from the treatment plan analysis set are basically consistent with the efficacy analysis set. It is worth noting that in this study, the weight loss rate of female participants was significantly higher than that of male participants
Petrelinide is a long-acting amygdalin analogue under development, which can be administered subcutaneously once a week. This molecule has been specially designed to exhibit excellent chemical and physical stability in a neutral pH environment, without fibrosis, and can be developed into compound formulations and co administered with other peptide drugs.
Starch is produced by pancreatic stellate cells and secreted together with insulin when nutrients are ingested. Activating the amylin receptor can restore the body's sensitivity to the satiety hormone leptin, thereby accelerating the production of satiety and ultimately achieving weight loss.
Eloralintide, a new weight loss drug from Eli Lilly, has been approved for clinical trials in Sichuan, China
On March 5, 2026, Eloralintide was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration to conduct three global key phase clinical trials in China simultaneously. To support the registration of this product in China for multiple indications such as weight management in the future, in order to meet the clinical needs of obese or overweight patients and their related comorbidities, and provide more effective and well tolerated treatment options. The results of the Phase 2 clinical study LAA1 showed that Eloralintide achieved clinically significant benefits in the secondary endpoints of weight loss and BM! Improvement compared to placebo in all dose groups. At 48 weeks of treatment, the drug showed a significant dose-dependent weight loss effect compared to baseline, with a maximum weight loss of 20.1% and a maximum average waist circumference reduction of 17.1cm. At the same time, loralintide can simultaneously improve multiple cardiovascular risk indicators such as waist circumference, blood pressure, blood lipids, blood glucose, and inflammatory markers.
|
|
|
|
In terms of safety, all doses of loralintide 1mg, 3mg, 6mg, and 9mg showed good safety and tolerability, with 9mg dose (no dose escalation) showing controllable tolerability; By adopting a 3/6/9mg incremental dosing regimen, Eloralintide can further reduce the incidence of gastrointestinal related adverse events. Eloralintide is a potent, selective, and long-acting amygdalin receptor agonist (AMYR) that can bind to human amygdalin 1 receptor (AMY1R) with high affinity while maintaining selectivity for human calcitonin receptor (hCTR). While maintaining weight loss effects, Eloralintide also improves gastrointestinal reactions, achieving a balance between efficacy and tolerability. Eloralintide's selectivity for amygdalin receptors can reduce potential risks associated with calcitonin receptor activity. Eloralintide is suitable for subcutaneous (SC) administration once a week due to its long plasma half-life (approximately 14 days).